Open AccessUse of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
Author(s) -
Joana Ferra,
Filipa Mousinho,
Francisca Miranda,
Sandra André,
Celina Afonso,
Fernando Nogueira
Publication year - 2021
Publication title -
european journal of case reports in internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2284-2594
DOI - 10.12890/2021_002345
Subject(s) - primary effusion lymphoma , medicine , brentuximab vedotin , lymphoma , oncology , chop , human immunodeficiency virus (hiv) , disease , pleural effusion , retrospective cohort study , immunology , cd30
Primary effusion lymphoma is a rare and aggressive large B-cell lymphoma presenting as malignant effusion with poor prognosis. Although it is more prevalent among HIV patients, it has also been described in non-HIV immunocompromised individuals. Given its rarity, there are no large randomized trials regarding the best therapeutic option. The choice of therapy is based on retrospective studies, case reports and preclinical data. We present the case of a non-HIV patient with relapsed disease after treatment with CHOP who was then successfully treated with brentuximab vedotin, achieving complete remission.